Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amolab is an Italian healthcare technology and medical device company founded in Lecce in 2011 as a spin-off of the National Research Council. The company develops automated, non-invasive diagnostic imaging and clinical support solutions, with a particular focus on obstetrics and pneumology. Its marketed products include SensUS Touch for quantitative ultrasound-based labor monitoring, SensUS Lung for automated lung ultrasound assessment and pneumonia scoring, and LaborSIM for intrapartum ultrasound training. Amolab combines portable hardware with proprietary software modules such as Lung 19 App, Pneumonia Score, Covid Index, and Amolab Suite to support standardized imaging workflows and reporting. The company appears to be a private, active medtech business rather than a therapeutics developer, and its value proposition centers on improving objectivity, safety, and usability in point-of-care ultrasound.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Amolab.